Clinical trial
A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected…
NCT00128830 · Tibotec Pharmaceuticals, Ireland, Industry · Completed
Key facts
| NCT number | NCT00128830 |
|---|---|
| Title | A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study |
| Official title | An Open-Label Trial With TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks |
| Lead sponsor | Tibotec Pharmaceuticals, Ireland, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus Type 1 |
| Intervention type | Drug |
| Interventions | Etravirine (ETR), Nucleotide reverse transcriptase inhibitors (NRTIs), Protease inhibitors (PIs), Enfuvirtide (ENF) |
| Enrollment | 211 |
| Start date | Jun 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Aug 10, 2005 |
| Last update posted | Jun 20, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: